Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients.

Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Abstract Text:

Sven Becker,Erich Solomayer,Graziella Becker-Pergola,Diethelm Wallwiener,Tanja Fehm,Sven Becker,Erich Solomayer,Graziella Becker-Pergola,Diethelm Wallwiener,Tanja Fehm,

INTRODUCTION: The presence of disseminated tumor cells in the bone marrow of breast cancer patients has proven to be an independent prognostic factor. The aim of this study was to investigate the status of tumor cell dissemination after primary systemic therapy in relation to therapy response. METHODS: Bone marrow aspirates were obtained from 120 patients after completion of primary systemic therapy. Disseminated tumor cells were detected by immunocytochemistry using the APAAP method. Bone marrow status was correlated with clinicopathological factors as well as tumor response to primary systemic therapy. RESULTS: Sixty out of 120 patients had disseminated tumor cells in their bone marrow aspirates (50%). Response rates were 18% for pathologic complete remission, 52% for partial remission, 28% for no change and 3% for progression. Despite complete remission, 36% of these patients were bone marrow positive. In the partial remission group, the positivity rate was 48%. About 61% of patients with stable disease had disseminated tumor cells in their bone marrow. A trend to higher positivity rates was observed in the poor responder group compared to responders (61% vs. 38%, P = 0.1). CONCLUSION: Primary systemic therapy does not completely eradicate disseminated tumor cells in the bone marrow of breast cancer patients. The biological role of persistent disseminated tumor cells needs to be further investigated to optimize current and future therapeutic strategies.

Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Publishing Authors By Initials

S Becker,E Solomayer,G Becker-Pergola,D Wallwiener,T Fehm,S Becker,E Solomayer,G Becker-Pergola,D Wallwiener,T Fehm,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Breast cancer research and treatment

VOLUME: 106

Page Numbers: 239-43

Journal Abbreviation: Breast Cancer Res. Treat.

ISSN: 0167-6806

DAY: 27

MONTH: 01

YEAR: 2007

Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8111104

Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients.

AFFILIATION: Department of Gynecology and Obstetrics, Tübingen University Hospital, Calwerstr. 7, 72076, Tübingen, Germany, sven.becker@med.uni-tuebingen.de.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Breast Cancer Res Treat

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients Related Publications

• Acute twin-twin transfusion syndrome: a case report.
• Changes in tumour biological markers during primary systemic chemotherapy (PST).
• Disturbed cortisol secretion in man: contrasting Cushing's disease and endogenous depression.
• Dose-dependent influences on electrophysiological signs of attention in humans after neuropeptide ACTH 4-10.
• Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients.
• Epidemiology and natural course of social fears and social phobia.
• Glucocorticoid influences on the auditory brain-stem responses in man.
• Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer.
• Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients.
• Tumor cell dormancy: implications for the biology and treatment of breast cancer.